Kymera Therapeutics, Inc. (KYMR)
Automate Your Wheel Strategy on KYMR
With Tiblio's Option Bot, you can configure your own wheel strategy including KYMR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KYMR
- Rev/Share 0.501
- Book/Share 10.8391
- PB 8.2719
- Debt/Equity 0.0888
- CurrentRatio 7.381
- ROIC -0.3182
- MktCap 6450949761.0
- FreeCF/Share -2.637
- PFCF -28.0224
- PE -26.5224
- Debt/Assets 0.0762
- DivYield 0
- ROE -0.3335
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | KYMR | Guggenheim | -- | Buy | -- | $90 | Nov. 3, 2025 |
| Reiterated | KYMR | B. Riley Securities | -- | Buy | $60 | $80 | Oct. 24, 2025 |
| Initiation | KYMR | Mizuho | -- | Outperform | -- | $81 | Oct. 21, 2025 |
| Reiterated | KYMR | H.C. Wainwright | -- | Buy | $60 | $70 | Sept. 18, 2025 |
| Initiation | KYMR | Barclays | -- | Overweight | -- | $60 | Sept. 17, 2025 |
| Initiation | KYMR | RBC Capital Mkts | -- | Outperform | -- | $70 | Sept. 16, 2025 |
| Resumed | KYMR | B. Riley Securities | -- | Buy | -- | $60 | July 30, 2025 |
| Resumed | KYMR | Morgan Stanley | -- | Overweight | -- | $70 | July 3, 2025 |
| Upgrade | KYMR | B. Riley Securities | Neutral | Buy | -- | $60 | June 3, 2025 |
| Upgrade | KYMR | Morgan Stanley | Equal Weight | Overweight | -- | $79 | June 3, 2025 |
News
Kymera's Eczema Drug Gets Fast Track Designation in the United States
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
Read More
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
Read More
This Drugmaker's Stock Is Soaring Over 40% Monday
Published: December 08, 2025 by: Investopedia
Sentiment: Positive
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Read More
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
Published: December 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
Read More
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
Published: December 08, 2025 by: Seeking Alpha
Sentiment: Positive
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, rapid onset, and meaningful biomarker and symptom improvements, supporting advancement to Phase 2b trials in AD and asthma. KYMR's $4.8B market cap reflects its validated protein-degradation platform and KT-621's commercial potential in large, crowded Type-2 inflammatory disease markets.
Read More
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Read More
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. ( KYMR ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Well, thank you, everyone, for joining us in our fireside chat with Kymera Therapeutics.
Read More
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
Read More
Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Here we go. So welcome to the second day of the Citi Biopharma, the Back to School Conference.
Read More
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
Read More
Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2025 Earnings Conference Call August 11, 2025 8:30 AM ET Company Participants Bruce N. Jacobs - Chief Financial Officer Jared A.
Read More
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.58 per share a year ago.
Read More
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile
Read More
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
Read More
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Read More
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Published: June 25, 2025 by: Reuters
Sentiment: Positive
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Read More
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Published: June 12, 2025 by: MarketBeat
Sentiment: Positive
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Read More
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
Read More
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using KT-621 to target patients with moderate-to-severe atopic dermatitis, expected Q4 of 2025. Robust pipeline in place, including a Sanofi partnership on KT-474 and a new IRF5 degrader, diversifies its immunology targeting market opportunity.
Read More
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile
Read More
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression
Read More
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Read More
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago.
Read More
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug
Read More
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not …
Read More
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT.
Read More
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, …
Read More
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Read More
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Andy Chen - Wolfe Research Paul Jeng - Guggenheim Ron Feiner - JPMorgan Jeff Jones - Oppenheimer Brad Canino - Stifel Marc Frahm - TD Cowen Ellie Merle - UBS Securities Parth Patel - Morgan Stanley Kripa Devarakonda - Truist Securities Eva Fortea-Verdejo - Wells Fargo Eric …
Read More
About Kymera Therapeutics, Inc. (KYMR)
- IPO Date 2020-08-21
- Website https://www.kymeratx.com
- Industry Biotechnology
- CEO Nello Mainolfi
- Employees 208